P2B001: Phase IIb started

Pharma Two began a double-blind, placebo-controlled, U.S. and Israeli Phase IIb trial to evaluate 2 doses of oral P2B001 once daily for 12 weeks in 150 patients with early PD. The company is developing the product under section 505(b)(2) of the Food, Drug and Cosmetic Act, which allows sponsors to reference data on safety and efficacy from scientific literature or from previously approved products. ...